CRISPR’s next act: the companies editing the epigenome to treat disease
1h ago
Source
bskyCRISPR’s next act: the companies editing the epigenome to treat diseasego.nature.comA feature in Nature reports how a handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder. 🧬🧪
You might also wanna read
Honda pivots from EV batteries to energy storage for data centers
Honda has begun producing batteries for energy storage systems destined for data centers, marking a strategic pivot away from its canceled U
techcrunch.com·53m agoUS factory activity eases off four-year high; input prices remain elevated
reuters.com·57m ago
NAVO neemt omstreden AI-systeem Palantir Maven Smart System in gebruik ondanks kritiek lidstaten
De NAVO heeft het Maven Smart System (MSS) van het Amerikaanse bedrijf Palantir in gebruik genomen voor haar digitale transformatie. Het AI-
nos.nl·1h agoIn Hindsight, Will a Coming Crash Seem Obvious?
bloomberg.com·1h ago
CRISPR gene therapy insights may improve access to sickle cell cures
nature.com·1h ago
Lab-created ‘SpudCell’ marks ‘stunning’ step toward building life from scratch
science.org·1h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.